Lewes, DE -- (SBWIRE) -- 07/11/2016 -- Report forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity.

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer.

Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs.

Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global solid tumors drugs market: F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS.

Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, and XBiotech.

Market driver
- Exposure to risk factors
- For a full, detailed list, view our report

Market challenge
- Patent expiration of top-selling drugs
- For a full, detailed list, view our report

Market trend
- Emergence of targeted and combination therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 156 pages and 104 Exhibit "Global Solid Tumors Drugs Market 2016 - 2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Cost analysis, Pipeline portfolio, Market segmentation by molecule type, Market segmentation by type of therapy, Market segmentation by disease, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://www.marketresearchreports.com/technavio/global-solid-tumors-drugs-market-2016-2020

Find all Healthcare reports at : http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions